Bellus Health Inc. (NYSE:BLU) has earned an average rating of “Buy” from the six brokerages that are currently covering the stock, MarketBeat.com reports. Five research analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have covered the stock in the last year is $16.00.
Several brokerages have recently weighed in on BLU. Jefferies Financial Group began coverage on Bellus Health in a research report on Monday, September 30th. They set a “buy” rating and a $20.00 target price on the stock. JBL Advisors began coverage on Bellus Health in a research report on Monday, September 30th. They set a “buy” rating on the stock. Cowen began coverage on Bellus Health in a research report on Monday, September 30th. They set an “outperform” rating on the stock. Guggenheim began coverage on Bellus Health in a research report on Monday, September 30th. They set a “buy” rating and a $12.00 target price on the stock. Finally, TheStreet raised Bellus Health from a “d+” rating to a “c-” rating in a research report on Friday.
Several institutional investors have recently made changes to their positions in the company. Orbimed Advisors LLC acquired a new stake in Bellus Health during the 3rd quarter worth $45,129,000. Millennium Management LLC purchased a new stake in shares of Bellus Health in the third quarter valued at about $424,000. Finally, Point72 Asset Management L.P. purchased a new stake in shares of Bellus Health in the third quarter valued at about $257,000.
NYSE:BLU opened at $8.30 on Tuesday. Bellus Health has a 1 year low of $2.63 and a 1 year high of $9.36. The business’s 50-day simple moving average is $7.13.
Bellus Health (NYSE:BLU) last issued its earnings results on Thursday, November 14th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.03). The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.01 million.
Bellus Health Company Profile
BELLUS Health Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various partnered development stage programs, including KIACTA for the treatment of sarcoidosis; AMO-01 for treatment of Phelan McDermid syndrome; and ALZ-801 for APOE4 homozygous Alzheimer's disease.
Receive News & Ratings for Bellus Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellus Health and related companies with .